Gram-negative bacteria can stimulate mucin production but excessive mucus supports bacterial infection and consequently leads to airway obstruction. Therefore the effect of dexamethasone (DEX) and the antioxidant acetyl-cysteine (ACC) on bacterial induced mucus expression was investigated.
INTRODUCTION
Chronic inflammatory lung diseases e. g. bronchial asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis are often associated with excessive mucus production especially in case of bacterial exacerbation. Mucus hypersecretion is also found in acute pulmonary infection as seen in acute bronchitis or pneumonia.
Bacteria can stimulate mucin expression via inflammation and inflammatory mediators. On the other hand bacterial products like lipopolysaccharide (LPS) have been demonstrated to directly induce mucin gene expression in cell culture systems and animal models (1, 2) . Although mucins are part of the innate immunity and help to clear bacteria from the lungs excessive mucus production can have deleterious effects. Mucus plugs can lead to pulmonary obstruction and support bacterial colonization and infection. Moreover, in clinical practice patients often complain about coughing and mucous secretions.
Gram-negative bacteria such as Haemophilus influenzae or Pseudomonas aeruginosa
can be frequently isolated from airway secretions of COPD or pneumonia patients with exacerbations (3, 4) . Previous studies in man have described signalling pathways by which LPS from Gram-negative bacteria can induce mucin gene expression (5) (6) (7) . In contrast, other parts of the outer cell membrane of Gram-negative bacteria such as lipoproteins are less well characterized for their ability to induce mucin expression.
At present there is no specific and good mucin regulating agent available. In clinical practice glucocorticosteroids are used to decrease mucus production by attenuating inflammation in the airways (8, 9) . Studies have confirmed the direct inhibition of mucin gene expression by dexamethasone (DEX) in cell culture and tissue culture experiments as well (10) (11) (12) . However, information on the direct effect of glucocorticosteroids on bacterial induced mucin expression is sparse.
Acetyl-cysteine (ACC) is a commonly used mucolytic that may perhaps act as an antiinflammatory drug and an antioxidant (13, 14) . A recent study has shown ACC to be ineffective in reducing the rate of exacerbations of COPD (15) . However, previous studies have shown that generation of reactive oxygen species (ROS) increased mucin gene expression by stabilization of mRNA (7, 16, 17) . Therefore we hypothesize that antioxidants may also reduce mucin expression.
The first aim of the present study was to investigate the effect of LPS and lipoprotein stimulation on mucin expression. We used explanted human airway mucosa as an ex vivo model and cell culture as an in vitro model. Our second aim was to evaluate the effect of DEX and ACC on LPS-and lipoprotein-induced mucin expression.
MATERIAL AND METHODS

Tissue culture
Upper airway mucosa (sinus) specimens were obtained from a total of 40 non-allergic and allergic individuals (16 male, 24 female, mean age 36 years). Allergic tissue was taken outside the allergen season and these patients did not receive any glucocorticosteroids. No pre-surgical Corticosteroids were given. Tissue was resected from patients undergoing sinus surgery, who had given informed consent before the procedure, and was rinsed in medium before culture. Serial sections of tissue were placed on 0.4-µm well inserts (Millipore, Bedford, MA) in 2 ml of defined medium as described previously (18, 19) and incubated in 5% CO 2 /95% air. Tissue was stimulated for 24 h as described below. Following culture, tissue was fixed using the HOPE (Hepes-Glutamic acid buffer mediated Organic solvent Protection Effect) technique (20) .
Cell culture
Mucus producing Calu-3 cells were grown in Eagle's Minimal Essential medium with Earl's BBS and 2 mM L-glutamine (EMEM) containing 1.0 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 1.5 g/L sodium bicarbonate, supplemented with 10% fetal bovine serum in 5% CO 2 /95% air. For in vitro cell culture experiments 100,000 cells were put in 2 ml of medium per each well in 6 well plates. After reaching confluence cells were starved for 24 hours in medium without serum and then stimulated for another 24 hours. After incubation cells were placed on cytospins for periodic acid Schiff (PAS) staining or lysed for RNA extraction.
Stimulation with LPS and PAM3
Tissue samples and Calu-3 cells were cultured for 24 hours in medium alone and in the Quantitative real time PCR (QRTPCR) QRTPCR was carried out using a LightCycler system (Roche Diagnostics, Mannheim, Germany). MUC5AC was selected to measure mucin gene expression because it encodes for the most important secreted mucin in human airways (21) . MUC5AC mRNA expression was quantified using QRTPCR. Delta-aminolevulinate synthase-1 (ALAS-1) was used as house keeping gene. Primers were based on published mRNA sequences for MUC5AC, and ALAS-
(GenBank Data Library accession numbers: AJ001402-MUC5AC, NM000688-ALAS-1)
and were designed to span at least two exons in order to avoid binding to genomic DNA.
Specific amplification using these primers was confirmed by ethidium bromide staining of the predicted size of the PCR products on an agarose gel. PCR was performed using the 
RESULTS
LPS and PAM3 induce mucin expression in vitro and ex vivo
LPS increased MUC5AC mRNA expression in Calu-3 cells in a dose-dependent manner (Fig.   1A ). The effect was significant at a concentration of 50 ng/mL (3-fold; P < 0.05). To ensure adequate stimulation LPS concentration of 200 ng/mL (5-fold) was used for subsequent stimulation experiments with DEX and ACC (see below). Mucin protein expression in Calu-3 cells was also increased in a dose-dependent manner following stimulation with LPS (Fig.   1B ). This effect was significant at a concentration of 10 ng/mL (60.8%±2.6% vs 33.5%±5.6%; P < 0.05). In explanted human airway mucosa LPS (10 ng/mL) significantly increased MUC5AC mRNA (3-fold; P < 0.05) (Fig. 1C) and mucin protein expression (55.0%±8.8% vs 37.5%±8.7%; P < 0.05) (Fig. 1D) .
Stimulation with the synthetic lipoprotein PAM3 caused a dose-dependent increase in expression of MUC5 mRNA in Calu-3 cells. This effect was significant at 200 nM (4-fold; P < 0.05) (Fig. 1A) . PAM3 also significantly increased mucin protein expression in Calu-3 cells at 200 nM (47.0%±10.9% vs 33.5%±5.6%; P < 0.05) (Fig. 1B) . In explanted mucosal tissue PAM3 significantly increased MUC5AC mRNA (2-fold; P < 0.05) (Fig. 1C) and mucin protein expression using 200 nM (52.5%±8.8% vs 37.5%±8.7%; P < 0.05) (Fig. 1D) .
Effect of LPS and PAM3 on inflammatory cells in airway submucosa
There was no significant change in the numbers of inflammatory cells in the submucosa of explanted human airways following stimulation with either LPS or PAM3 alone (P > 0.05).
Effect of dexamethasone on LPS and PAM3 induced mucin expression in human airway mucosa Stimulation with different concentrations of dexamethasone (0.1 µM, 0.4 µM, 1.0 µM, 4.0 µM, 40 µM, and 400 µM) alone had no significant effect on epithelial mucin expression in explanted human airway mucosa (P > 0.05) ( Fig. 2A) . In contrast DEX significantly reduced LPS-and PAM3-induced mucin expression in a dose-dependent manner when given at the same time. The effect was significant at concentrations 1.0 µM after stimulation with LPS (45.8%±4.2% vs 57.5%±4.4%; P < 0.05) or PAM3 (40.6%±7.9% vs 47.5%± 5.5%; P < 0.05) (Fig. 2B, C) . This inhibition is seen in original histology photographs as shown in Fig. 2D -H.
Pre-stimulation with DEX at concentrations ranging from 0.1 µM to 40 µM resulted in decreased ability of LPS and PAM3 to induce epithelial mucin expression compared to stimulation with LPS or PAM3 alone. Attenuation of LPS-or PAM3-induced mucin expression was dose dependent. The effect was statistically significant at DEX concentrations of 1.0 µM for LPS (43.8%±2.5% vs 56.3%±3.5%; P < 0.05) and PAM3 (31.3%±3.5% vs 43.8%±3.5%; P < 0.05) (Fig. 3) .
Effect of dexamethasone on LPS-and PAM3-induced mucin expression in vitro
Stimulation with different concentrations of DEX alone (0.1 µM-400 µM) had no significant effect on MUC5AC mRNA and mucin protein expression in Calu-3 cells (P > 0.05). DEX significantly decreased LPS-and PAM3-induced MUC5AC mRNA expression in dosedependantly (Fig. 4A, C) . The effect was significant concentrations 0.4 µM (P < 0.05).
Moreover, DEX reduced LPS-and PAM3-induced mucin protein expression in a dosedependent manner (Fig. 4B, D) . This effect was statistically significant at 0.4 µM for LPS stimulation (34.0%±1.1% vs 39.4%±1.0%; P < 0.05) and 1.0 µM for PAM3 stimulation (28.0%± 0.5% vs 35.2%± 7.2%; P < 0.05).
Pre-stimulation with DEX (0.1 µM-400 µM) reduced the ability of LPS and PAM3 to upregulate epithelial MUC5AC mRNA and mucin protein expression compared to stimulation with LPS or PAM3 alone ( fig. 5 ). Attenuation of LPS-or PAM3-induced MUC5AC and mucin protein expression was dose-dependent. The effect was statistically significant at DEX concentrations 1.0 µM for LPS-induced MUC5AC mRNA expression and mucin protein expression (27.8%±6.5% vs 38.6%±1.1%; P < 0.05) (Fig. 5 A, C) . PAM3-induced MUC5AC mRNA expression was significantly decreased by pre-incubating with DEX concentrations 0.4 µM whereas mucin protein expression was significantly reduced at DEX concentrations of 1.0 µM (27.5%±1.9% vs 34.3%±3.8%; P < 0.05) (Fig. 5 B, D) .
Using DMSO as a diluent for DEX did not significantly affect its potency. DEX decreased LPS-and PAM3-induced MUC5AC mRNA and mucin protein expression in a dose-dependent manner (Fig. 6A-D) . This effect was significant at concentrations of 1.0 µM (P < 0.05).
Effect of RU486 on dexamethasone induced attenuation of mucin expression in human airway mucosa and in vitro Addition of RU486 (1.0 µM) partly inhibited the suppressive effect of DEX on LPS-and PAM3-induced mucin expression in human airway mucosa (Fig. 7A-B) . This effect was significant for stimulation with LPS and DEX (66.7%±4.2% vs 45.8%±4.3%; P < 0.05) and for PAM3 and DEX (41.7%±4.2% vs 29.3%±4.3%; P < 0.05).
In Calu-3 cells RU486 also inhibited in part DEX mediated suppression of LPS- (Fig.   8A , B) and PAM3-induced ( Fig. 8C; D) MUC5AC mRNA (Fig. 8A, C) and mucin protein expression (Fig. 8B, D) . It significantly attenuated the effect of DEX on LPS-and PAM3-induced MUC5AC mRNA expression (about 2-fold increase; P < 0.05). RU486 also significantly increased LPS-and PAM3-induced mucin protein expression in the presence of DEX (55.0%±5.0% vs 39.0%±1.0% and 45.5%±4.3% vs 32.5%±5.4%, respectively; P < 0.05).
Effect of acetyl-cysteine (ACC) on LPS-and PAM3-induced mucin expression in human airway mucosa Stimulation with different concentrations of acetyl-cysteine (ACC at 0.3 mM, 3.0 mM, and 30.0 mM, respectively) alone increased epithelial mucin expression in explanted human airway mucosa in a dose-dependent manner (Fig. 9A ). This effect was statistically significant at 3.0 mM (60.0%±6.0% vs 33.3%±2.8%; P < 0.05). However, ACC inhibited the LPSinduced mucin protein expression in a dose-dependent manner. This effect was significant at all used concentrations (58.3%±4.3% vs 37.5%±7.3%, 35.0%±7.3%, and 31.3%±12.0%, respectively; P < 0.05) (Fig. 9B) . ACC also significantly decreased PAM3-induced mucin protein expression at similar concentration (50.0%±9.3% vs 31.3%±6.3%; P < 0.05) (Fig.   9C ). Original histology photographs are shown in Fig. 9D -G.
Effect of acetyl-cysteine on LPS-and PAM3-induced mucin expression in vitro
In Calu-3 cells stimulation with different concentrations of ACC alone had no significant effect on MUC5AC mRNA and mucin protein expression (P > 0.05). However, ACC decreased both LPS-and PAM3-induced MUC5AC mRNA expression by approximately one third but this effect was not significant (p > 0.05) (Fig. 10A, C) . In contrast LPS-induced mucin protein expression was significantly decreased at 0.3 mM ACC (25.8%±6.7% vs 53.5%±6.7%; P < 0.05) whereas higher concentrations of ACC had no significant effect (53.3%±6.7% vs 38.1%±5.7%, and 41.9%±5.9%, respectively; P > 0.05) (Fig. 10B ). PAM3-induced mucus protein expression was not significantly reduced in the presence of ACC at all used concentrations (48.5%±4,5% vs 34.4%±12.8%, 35.2%±6.9%, and 38.7%±11.9%, respectively; P > 0.05) (Fig. 10D) .
DISCUSSION
In the present study the effect of DEX and ACC on LPS and PAM3 induced mucin expression were investigated. The rationale for this study was that these drugs are commonly used in clinical practice to reduce and ameliorate mucus hypersecretion. However, studies looking at the cellular level of action are sparse.
LPS has been shown previously to increase mucin gene expression and to induce mucous metaplasia (1, 2) . Our data agree with those findings. We also found a dosedependent increase in MUC5AC mRNA and mucin protein expression both in nasal mucosal tissue and in mucus-producing cells.
Since other parts of the outer membrane wall of Gram-negative bacteria such as lipoproteins may also stimulate mucin expression, PAM3 was used as a synthetic lipoprotein.
However, there is no specific information available on the effect of PAM3 on mucin expression in the lungs. A previous study found increased mucin expression in an animal model of mycoplasma infected mice (24) . In that study lipoprotein from mycoplasma induced mucin expression via TLR2-signalling. In our study PAM3 also increased MUC5AC mRNA and mucin protein expression ex vivo and in vitro in dose-dependent manner however, its effect was weak compared to stimulation with LPS. Higher concentrations of PAM3 than those used in this study (> 200 nM) did not have a stronger effect (data not shown).
Both LPS and PAM3 had no significant effect on the total numbers of monocytes, and TLR-4 (for LPS) has been shown in epithelial as well as in inflammatory cells (25, 26) .
Most previous studies have investigated the effect of DEX on unstimulated epithelial cells or tissue (10) (11) (12) 22) . Information regarding the effect of DEX on bacterial induced mucin expression is sparse despite its use in clinical practice. For this reason we investigated the effect of DEX on bacterial induced mucus production. Since glucocorticoid therapy is known to reduce airway inflammation in vivo (8) , it is reasonable to invisage that glucocorticoids reduce inflammation-induced mucus hypersecretion. Beclomethasone dipropionate has previously been reported to significantly reduce inflammation and mucin production in patients with cystic fibrosis (9) . In vitro studies have shown that DEX transcriptionally mediates repression of MUC5AC gene expression (10, 11, 22) and in cultured human airways DEX decreases the basal rate of mucus secretion (12) . Such studies to date have predominantly used A549 and NCI-H292 cells. The disadvantage of these studies is that A549 cells are derived from type 2 pneumocytes and may therefore not be the best cells to investigate mucin expression while NCI-H292 cells which are commonly used to examine mucin expression (27) have high baseline or constitutive mucin production. In our study we used Calu-3 cells which is a mucoepidermoid cell line that can be easily stimulated to express mucin. Interestingly, in this cell line we did not observe reduced mucin production at protein level in the presence of DEX as previously described (12) . These data suggest that the effect of DEX may vary in different cell lines. Our results also support the notion that data from one cell line may not apply to what is seen in a clinical setting.
DEX significantly decreased LPS-and PAM3-induced MUC5AC mRNA and mucin protein expression in vitro. These data agree with previous findings that show direct inhibition of mucin gene expression by glucocorticosteroids (10, 11, 21) .
Interestingly tissue and cells pre-stimulated with DEX did not have a stronger inhibitory effect on LPS-and PAM3-induced MUC5AC mRNA and mucin protein expression compared to stimulation done at the same time. In a previous study by Chen and colleagues MUC5AC mRNA expression in A549 cells was significantly decreased by DEX at a concentration of 100 nM from 6 hours post stimulation (10). In our experiments tissue and Calu-3 cells were pre-incubated with DEX for 16 hours before LPS or PAM3 was added.
However, pre-stimulation with DEX significantly decreased MUC5AC mRNA expression at a concentration of 400 nM (0.4 µM). Mucin protein expression in explanted tissue was significantly decreased at a concentration of 1000 nM (1.0 µM). This data indicate that higher concentrations of DEX may required to reduce mucin expression in an ex vivo model and in different cell lines (as stated above). To ensure that the effect of DEX was not influenced by the solvent we also tested the effect of DEX dissolved in DMSO. However, DMSO had no significant effect on the potency of DEX to attenuate mucin expression.
Another possibility is that the effect of DEX is not mediated by binding to the glucocorticoid receptor alone. Moreover, our findings suggest that DEX may not exclusively decrease mucus production by suppressing mucin gene expression alone but DEX may also have inhibitory effects on mucin protein production and secretion however, this remains to be further investigated. In our experiments the glucocorticoid receptor inhibitor RU486 had a significant effect on DEX-induced attenuation of mucin expression. RU486 blocked most of the suppressive effect of DEX on LPS-and PAM3-induced mucin expression. This finding indicates that in fact the greatest part of the effect of DEX is mediated via the glucocorticoid receptor.
An increase in reactive oxygen species (ROS) has been shown to stimulate mucin gene expression in cell culture (7, 16, 17) . Since ACC has potent antioxidative properties we investigated the effect of ACC on bacterial induced mucus expression. In contrast to our expected results in explanted human airway mucosal tissue ACC alone increased mucin expression but LPS-or PAM3-induced mucin expression was decreased. It seems that ACC alone can act as a strong secretagogue and may therefore be benefitial in patients to enhance expectoration and improve mucociliary clearance. On the other hand ACC may also function as an antioxidant that decreases LPS-or PAM3-induced generation of ROS and mucin expression. In a previous study a protective role of ACC in a rat model of bleomycin-induced lung fibrosis was described (28) . In that study ACC decreased bleomycin-induced mucin protein expression. However, a small non statistically significant increase in mucin protein expression could be noted with ACC alone. This finding supports the notion that ACC alone can increase mucin protein expression. Interestingly in that study no change in Muc5AC gene expression was observed with ACC alone. It is possible that ACC acts on the posttranscriptional level. This remains to be further studied.
Most-recent study looked at the effect of high concentrations of ACC in endothelial cell culture (29) . In that study tumor necrosis factor--generated oxidized glutathione levels were higher post treatment with ACC at a concentration of 30 mM compared to pre-treatment with ACC at 3 mM. This data indicates that excess of anti-oxidative agents may cause further stress with generation of ROS. In that study high concentrations of ACC caused glutathionylation of IKK thereby inhibiting its activity that in turn enhanced NF-B activation (29) . In our study we used ACC concentrations between 0.3 mM and 30 mM therefore ROS may be generated in unstimulated explanted mucosal tissue leading to increased mucin expression. Unfortunately we did not measure glutathione levels in this study as this was beyond the scope of our study.
The inhibition of ACC on LPS-and PAM3-induced mucin expression in cell culture experiments failed to reach statistical significance but this may be due to the small number of experiments. However, ACC had a significant effect in explanted human airway mucosa (ex vivo) thereby suggesting that ACC may also be effective in vivo.
Experiments using different types of LPS (e. g. derived from Pseudomonas aeruginosa or Haemophilus influenzae) showed LPS-induced MUC5AC mRNA and mucin protein expression that could be attenuated by DEX or ACC (data not shown). Therefore DEX and ACC may be effective in bacterial infection with different strains.
Although DEX and ACC are commonly used in clinical practice the effect of these drugs on bacterial induced mucus expression has not been fully investigated. In the present study we used an ex vivo model to investigate the effect of DEX and ACC. This model is close to the in vivo situation. However, there is no systemic circulation and inflammatory cells are limited in their ability to migrate. Nevertheless our study provides a link from basic research to clinical work.
In summary in the present study we demonstrated stimulation of mucin expression by Gram-negative bacterial membrane products in explanted human airway mucosal tissue. Both DEX and ACC decreased epithelial mucin expression. From this data it seems that DEX had a stronger effect than ACC. However, we did not perform direct comparison of these effects.
DEX and ACC may be used to reduce mucus hypersecretion in case of bacterial infection or exacerbation. Although patients may have a clinical benefit (less mucus, less coughing) it remains to be further investigated whether this can affect prognosis. 
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